NASD · Healthcare · Drug Manufacturers - Specialty & Generic · China
Zhengye Biotechnology Holding Ltd is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Zhengye Biotechnology Holding Ltd stock.
Overvalued: intrinsic value $0.69 per share, market price $1.30, margin of safety -87.9% (as of 2026-10-30).
Its through-the-cycle earnings (15.0% median margin), capitalised at 8.9% with no growth, values the shares at $0.69; the price of $1.30 is 88% above that value.
All 84 Drug Manufacturers - Specialty & Generic stocks
19 more in this industry show a wider margin of safety.
ZYBT is overvalued (as of the 2026-10-30 close). Its through-the-cycle earnings (15.0% median margin), capitalised at 8.9% with no growth, values the shares at $0.69; the price of $1.30 is 88% above that value.
$0.69 per share (as of the 2026-10-30 close), against a market price of $1.30. That is a margin of safety of -87.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.